- About the Center
- Patient Care
- Community Outreach
- Academic Programs
- News & Media
University of Arizona Cancer Center researchers M. Peter Lance, MD, FRCP, and Steven P. Stratton, PhD, have been selected as the 2012 recipients of the Sydney E. Salmon, MD, distinguished senior investigator award and distinguished junior investigator award, respectively.
The Salmon Awards are presented in memory of the UA Cancer Center’s founding director, Sydney E. Salmon, MD, whose birthday is May 8. Drs. Lance and Stratton will receive their awards and present their latest research findings on May 8 at 2 p.m. in Kiewit Auditorium. The Salmon Awards recognize Arizona Cancer Center faculty members for their leadership in cancer research, grant support, publications, community service and clinical responsibilities.
Dr. Lance is a professor of medicine, molecular and cellular biology and public health at the University of Arizona. He is also the University of Arizona Cancer Center’s chief cancer prevention and control officer and medical director of the CaTS Clinical Research Unit.
Dr. Lance obtained his undergraduate and medical degrees from the University of Cambridge in England. He completed residency and fellowship training in internal medicine and gastroenterology in England at the Universities of Birmingham and London. He came to the United States in 1981 as a postdoctoral fellow at the University of California, San Francisco, where he established his interest in colorectal cancer—the focus of his research ever since.
In 1982, he moved to a junior faculty position at Brown University. There, he further developed his research interests in gastrointestinal oncology and became board certified in internal medicine and gastroenterology. In 1987, he was recruited to a joint appointment at the University of Buffalo and Roswell Park Cancer Institute. During the next 14 years, he progressed to the rank professor of medicine, physiology and biophysics, and became chief of the gastroenterology division.
A member of UA Cancer Center since 2001, Dr. Lance’s clinical and translational research in Arizona has focused on the prevention and early detection of colorectal cancer. This includes a randomized trial of celecoxib and selenium supplementation for the prevention of colorectal polyp recurrence. With Dr. Patricia Thompson as joint principal investigator, he is studying the effects of selenium supplementation on Type 2 diabetes risk. He is principal investigator of an R01 to investigate the effects of selenium and vitamin E on colorectal neoplasia-related endpoints in the 35,000 participants of the SELECT Trial of these interventions for prostate cancer prevention.
Dr. Lance’s service and outreach efforts include piloting CT colonography for colorectal cancer screening in Native Americans of the Navajo Nation. He is medical director for the Arizona Department of Health Services colorectal cancer screening program. He serves on the University of Arizona Committee on Promotion and Tenure. He is an elected Fellow of the Royal College of Physicians of London.
Dr. Stratton is an associate professor of medicine at the University of Arizona and a member of the University of Arizona Cancer Center’s Cancer Prevention and Control Program, is the recipient of the Distinguished Junior Investigator Salmon Award.
Dr. Stratton received his BA in chemistry from Gustavus Adolphus College and his PhD in pharmacology and toxicology from the University of Arizona. Dr. Stratton has expertise in oncology drug development including design of basic and clinical studies to uncover mechanisms of new cancer chemopreventive and chemotherapeutic agents.
His basic science research interests include use of chromatography and mass spectrometric techniques to study the role of membrane lipids in UV-induced skin cancer, pharmacology and toxicology of topical drugs, and discovery of new biomarkers for diagnosis and prognosis of prostate cancer.
He serves as clinical project leader and co-leader of the Drug Development Core Service in the UACC’s National Cancer Institute-funded Chemoprevention of Skin Cancer Program Project. He also serves as co-director of the analytical chemistry service laboratory and co-director of the Prostate Cancer Prevention Program in the UACC.
He is trained in analytical chemistry and experienced in preclinical development of topical drugs, and has served on an NCI/FDA/AACR task force for treatment of intraepithelial neoplasia. He has been an invited speaker at national and international meetings and has served as a consultant to the biotechnology industry for the past twelve years. He is also chair of the Scientific Review Committee at the Cancer Center.
April 30, 2012